Skip to main content
PegBio Co., Ltd. logo

PegBio Co., Ltd. — Investor Relations & Filings

Ticker · 2565 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 2,123 across all filing types
Latest filing 2025-05-19 Audit Report / Informat…
Country HK Hong Kong
Listing HKEX 2565

About PegBio Co., Ltd.

http://www.pegbio.com

PegBio Co., Ltd. is a biotechnology company specializing in the in-house discovery and development of innovative therapies for chronic diseases, primarily focusing on the endocrine and metabolic fields. The company leverages its proprietary HECTORTM technology system to design and screen novel molecular entities, including peptide, protein, and small-molecule drugs, targeting unmet clinical needs. PegBio's robust pipeline addresses major chronic conditions such as Type 2 Diabetes (T2DM), obesity, and metabolic dysfunction-associated steatohepatitis (MASH). Key pipeline assets include long-acting GLP-1 receptor agonists, such as Vepinatide, developed for T2DM treatment and weight management. The company emphasizes creating complementary, multi-benefit product pipelines characterized by new targets, new sites, and new mechanisms of action.

Recent filings

Filing Released Lang Actions
Documents on Display
Audit Report / Information Classification · 1% confidence The document is a short landing page or index from the HKEX news portal listing various supplementary documents (Articles of Association, Audited Financials, Accountants' Report, etc.) related to a 'Global Offering' for PegBio Co., Ltd. Since the document itself is a brief index/announcement providing links to these reports rather than the reports themselves, it falls under the category of a Report Publication Announcement (RPA). FY 2024
2025-05-19 English
GLOBAL OFFERING
Share Issue/Capital Change Classification · 1% confidence The document is the full IPO prospectus (“Prospectus”) for PegBio’s global offering of new H shares, detailing share counts, offer price, underwriting arrangements, application procedures and expected timetable. It is not an earnings release, annual report or AGM material, but a detailed offer document for a new share issue. Under the provided taxonomy, this best fits “Share Issue/Capital Change” (SHA).
2025-05-19 English
GLOBAL OFFERING
Share Issue/Capital Change Classification · 1% confidence The document is an official exchange announcement detailing the terms of the Company’s Global Offering, including number of shares issued, offer price, allocation structure and listing timetable. It constitutes a new share issuance / capital change (an equity fundraising). It is not a proxy, AGM material, earnings release or full prospectus but specifically an announcement of a share issue. Therefore it matches the Share Issue/Capital Change category.
2025-05-19 English
OC Announcement - Appointment (Revised)
Capital/Financing Update Classification · 1% confidence The document is an announcement pursuant to the Hong Kong Listing Rules regarding the appointment of overall coordinators (underwriters) for the company’s proposed securities offering and listing. It does not present financial results, nor is it a full prospectus; rather, it is an update on financing arrangements in the IPO process. This aligns with a Capital/Financing Update (Code: CAP).
2025-05-15 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 1% confidence The document is a regulatory disclosure return (FF305) under the Hong Kong Stock Exchange Listing Rules, detailing changes in issued shares and treasury shares, specifically multiple on-market repurchases and cancellations of the company’s own shares. This aligns with the “Transaction in Own Shares” category (code: POS) which covers share buybacks and repurchases by the company. It is not an earnings release, annual report, or governance update, but rather a detailed report of share transactions undertaken by the issuer.
2025-05-15 English
DISCLOSEABLE TRANSACTION IN RELATION TO ACQUISITION OF NOTES
Capital/Financing Update Classification · 1% confidence The document is a Hong Kong Stock Exchange announcement by CMBC Capital Holdings Ltd. regarding a Chapter 14 discloseable transaction: the acquisition of US$10,000,000 of Citigroup Inc. notes. It provides transaction details, listing rules implications, and principal terms of the Notes. It is not an annual or interim report, nor a management change, earnings release, or proxy statement. It reports a financing-related transaction (acquisition of debt securities), matching the “Capital/Financing Update” category.
2025-05-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.